KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Research & Development (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Research & Development for 7 consecutive years, with $28.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 8.82% to $28.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $121.0 million through Dec 2025, down 2.2% year-over-year, with the annual reading at $121.0 million for FY2025, 2.2% down from the prior year.
  • Research & Development hit $28.9 million in Q4 2025 for GoodRx Holdings, down from $31.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $39.6 million in Q3 2023 to a low of $26.2 million in Q1 2021.
  • Historically, Research & Development has averaged $32.5 million across 5 years, with a median of $31.5 million in 2023.
  • Biggest five-year swings in Research & Development: skyrocketed 153.37% in 2021 and later fell 23.91% in 2024.
  • Year by year, Research & Development stood at $35.1 million in 2021, then increased by 4.88% to $36.8 million in 2022, then fell by 12.89% to $32.0 million in 2023, then decreased by 0.91% to $31.7 million in 2024, then fell by 8.82% to $28.9 million in 2025.
  • Business Quant data shows Research & Development for GDRX at $28.9 million in Q4 2025, $31.0 million in Q3 2025, and $29.9 million in Q2 2025.